IP Library Granted Patent US 8,680,261
Granted Patent B2
US 8,680,261 · App. 12/796,961 · Granted Mar 25, 2014

Methods for purifying nucleic acids

Inventors: Robert Bridenbaugh (Milbrae, CA); Warren Dang (Alameda, CA); Lee B. Bussey (San Mateo, CA)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,680,261
App. No.
12/796,961
Granted
Mar 25, 2014
Kind
B2
Abstract

Methods are provided for producing highly purified compositions of nucleic acids by using a highly streamlined and readily automated process. The methods use static mixers for lysing cells and precipitating debris, following by centrifugation and ion exchange chromatography. The process may include a purification step using tangential flow ultrafiltration. A scaleable process for producing pharmaceutical grade plasmid DNA, useful for gene therapy, is provided.

Claims (12)

1. A method for purifying plasmid DNA from a solution containing plasmid DNA, comprising the steps:

a) contacting said solution with a precipitation solution;

b) flowing the solution obtained in step a) through a static mixer under conditions of flow that provide Reynolds numbers in the range of about 50 to 500;

c) further purifying said plasmid DNA using an open tangential flow ultrafiltration (TFU) under conditions that promote formation of a gel layer and said plasmid DNA is retained in a retentate solution;

d) contacting said retentate solution obtained in step c) with an ion exchange chromatography resin under conditions in which plasmid DNA is bound to said resin; and

e) eluting said plasmid DNA from said resin using a step gradient or a continuous gradient of a salt solution with increasing conductivity.

2. The method of claim 1 , further comprising exposing said solution obtained by step c) to a ribonuclease (RNAase).

3. The method of claim 1 , said ion exchange chromatography resin being an anion exchange chromatography resin.

4. The method of claim 1 , said ion exchange resin being a strong anion exchange chromatography resin.

5. The method of claim 1 , wherein said TFU is carried out using an ultrafiltration membrane having a molecular weight cutoff (MWCO) of 300 K Daltons, said plasmid DNA having sizes in the range of 2 Kb to 15 Kb being retained in said retentate solution.

6. The method of claim 1 , wherein said TFU is carried out using an ultrafiltration membrane having a MWCO of 500 K Daltons, said plasmid DNA having sizes in the range of 15 Kb to 50 Kb being retained in said retentate solution.

7. The method of claim 1 , wherein said TFU is carried out using an ultrafiltration membrane having a MWCO of 1000 K Daltons, said plasmid DNA having a size greater than 40 Kb being retained in said retentate solution.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2015
From: TRIPLEPOINT CAPITAL LLC
To: JUVARIS BIOTHERAPEUTICS, INC.
Reel/Frame 036739/0195 →
SECURITY AGREEMENT Recorded Oct 4, 2011
From: JUVARIS BIOTHERAPEUTICS, INC.
To: TRIPLEPOINT CAPITAL LLC
Reel/Frame 027015/0765 →
MERGER Recorded Oct 6, 2010
From: VALENTIS, INC.
To: URIGEN PHARMACEUTICALS, INC.
Reel/Frame 025095/0274 →
Continuity (3)
Continuation 09121798 · Jul 23, 1998
Continuation In Part 08691090 · Aug 1, 1996
Related Publication 20100248336A1 · Sep 30, 2010